Nearly 200 years ago, scientists first learned that the female body contains eggs. Since then, it became an accepted fact that a woman was born with a set number of eggs and those eggs die over time. One of the world’s most fundamental understandings about pregnancy was based on an image of a ticking biological clock.
One of OvaScience’s scientific founders, Jonathan Tilly, Ph.D., had the first of many breakthroughs that would challenge these long-held beliefs. He discovered the existence of egg precursor (EggPCSM) cells in the ovaries of adult mice. Subsequent research demonstrated that EggPC cells also exist in human ovaries and have the potential to develop into mature eggs, thereby replenishing a woman’s egg supply.
The presence of EggPC cells changes what we know about female biology and opens up extraordinary possibilities to help women improve their fertility. OvaScience was founded in 2011 to create new treatment options that leverage a woman’s own EggPC cells. The Company’s first treatment, the AUGMENTSM treatment, was introduced at certain IVF centers in select international markets in 2014. The AUGMENT treatment is not available in the United States.